These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Incomplete factorial designs for randomized clinical trials. Byar DP; Herzberg AM; Tan WY Stat Med; 1993 Sep; 12(17):1629-41. PubMed ID: 8235181 [TBL] [Abstract][Full Text] [Related]
26. Revisiting sample size: are big trials the answer? Lurati Buse GA; Botto F; Devereaux PJ J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():75-9. PubMed ID: 22810453 [TBL] [Abstract][Full Text] [Related]
27. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F; Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053 [No Abstract] [Full Text] [Related]
28. Review of randomized controlled trials: issues to consider when designing a trial. Pandis N Am J Orthod Dentofacial Orthop; 2013 Jun; 143(6):905-7. PubMed ID: 23726342 [No Abstract] [Full Text] [Related]
29. Design and analysis of experiments. Shuster JJ Methods Mol Biol; 2007; 404():235-59. PubMed ID: 18450053 [TBL] [Abstract][Full Text] [Related]
30. An examination of effect estimation in factorial and standardly-tailored designs. Allore HG; Murphy TE Clin Trials; 2008; 5(2):121-30. PubMed ID: 18375650 [TBL] [Abstract][Full Text] [Related]
31. Two-stage designs for cross-over bioequivalence trials. Kieser M; Rauch G Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815 [TBL] [Abstract][Full Text] [Related]
32. Survival trial design and monitoring using historical controls. Wu J; Xiong X Pharm Stat; 2016 Sep; 15(5):405-11. PubMed ID: 27307025 [TBL] [Abstract][Full Text] [Related]
33. Evaluating dynamic treatment strategies: does it have to be more costly? Buyze J; Goetghebeur E Pharm Stat; 2013; 12(1):35-42. PubMed ID: 23208788 [TBL] [Abstract][Full Text] [Related]
35. Sample size calculations for the design of cluster randomized trials: A summary of methodology. Gao F; Earnest A; Matchar DB; Campbell MJ; Machin D Contemp Clin Trials; 2015 May; 42():41-50. PubMed ID: 25766887 [TBL] [Abstract][Full Text] [Related]
36. Optimal designs for two-arm, phase II clinical trial design with multiple constraints. Mayo MS; Mahnken JD; Soong SJ J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252 [TBL] [Abstract][Full Text] [Related]
37. Use and interpretation of composite end points in orthopaedic trials. Busse JW; Bhandari M; Ferreira-González I; Montori VM; Guyatt GH J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():65-9. PubMed ID: 22810451 [TBL] [Abstract][Full Text] [Related]
38. The cohort multiple randomized controlled trial design: a valid and efficient alternative to pragmatic trials? van der Velden JM; Verkooijen HM; Young-Afat DA; Burbach JP; van Vulpen M; Relton C; van Gils CH; May AM; Groenwold RH Int J Epidemiol; 2017 Feb; 46(1):96-102. PubMed ID: 27118559 [TBL] [Abstract][Full Text] [Related]